华北制药财务风险分析及控制研究

发布时间：2018-03-24 23:04

本文选题：华北制药　切入点：财务风险　出处：《黑龙江八一农垦大学》2017年硕士论文

【摘要】：医药制造业是关系民生问题的重要行业,随着经济社会的进步与发展,健康问题成为人们关注的焦点,因此医药制造业的发展也更加受到国家和人民的关注。与发达国家相比,现阶段我国医药制造企业普遍缺乏自主创新能力,多数企业生产的医药产品技术含量较低,缺乏具有自主知识产权的产品,加之我国医药市场竞争愈发激烈,使我国医药制造企业出现财务风险在所难免。如何在企业出现财务风险时对其进行有效控制,是我国医药制造企业现阶段所面临的主要问题之一。华北制药股份有限公司,简称华北制药,是我国最大的制药企业之一,以该公司作为研究对象,运用文献研究法、归纳分析法以及因子分析法,对其近五年的财务状况,从筹资、投资、营运和分配四个方面进行风险识别。选取2015年度我国142家医药制造业上市公司的财务指标数据以及华北制药自建厂以来各年的财务数据作为样本,分别从横向和纵向评价华北制药的财务风险水平。通过研究得出,华北制药近五年财务风险较大,偿债能力和盈利能力均较弱,融资方式单一,负债规模相对较大,资本结构不合理,投资决策缺乏科学性,存货和应收账款管理不善,收益分配制度不合理。最后,从四个方面为华北制药提出相对合理的财务风险控制对策,包括发展多元融资方式,控制负债规模;加强投资风险管理,增加创新项目投资;加强对应收账款和存货的管理,健全内控机制;改进收益分配制度。以期为华北制药控制财务风险提供合理化建议,同时为其他医药制造企业财务风险的控制提供参考和借鉴。
[Abstract]:Pharmaceutical manufacturing industry is an important industry related to people's livelihood. With the progress and development of economy and society, health problems have become the focus of people's attention. Therefore, the development of pharmaceutical manufacturing industry is paid more attention by the country and the people. Compared with the developed countries, At present, the pharmaceutical manufacturing enterprises in our country generally lack the ability of independent innovation, the technology content of the pharmaceutical products produced by most enterprises is relatively low, and the products with independent intellectual property rights are lacking. In addition, the competition in the pharmaceutical market of our country is becoming more and more fierce. It is hard to avoid the emergence of financial risks in pharmaceutical manufacturing enterprises in China. How to effectively control the financial risks when they occur is one of the main problems faced by pharmaceutical manufacturing enterprises in China at the present stage. Huabei Pharmaceutical is one of the largest pharmaceutical enterprises in China. Taking this company as the research object, using literature research method, inductive analysis method and factor analysis method, to its financial situation in the past five years, from financing, investment, Selecting the financial index data of 142 listed pharmaceutical manufacturing companies in China in 2015 and the financial data of Huabei Pharmaceutical Company since the establishment of the factory as a sample. The financial risk level of Huabei Pharmaceutical Company has been evaluated horizontally and vertically. The results show that North China Pharmaceutical Company has a higher financial risk in the past five years, weak solvency and profitability, a single way of financing, and a relatively large scale of liabilities. The capital structure is unreasonable, the investment decision is not scientific, the inventory and accounts receivable are not well managed, and the income distribution system is unreasonable. Finally, the relative reasonable financial risk control countermeasures are put forward for North China Pharmaceutical Company from four aspects. It includes developing multiple financing methods, controlling debt scale, strengthening investment risk management, increasing investment in innovative projects, strengthening the management of accounts receivable and inventory and perfecting internal control mechanism. In order to provide reasonable advice for North China Pharmaceutical Company to control financial risk and to provide reference for other pharmaceutical manufacturing enterprises to control financial risk.
【学位授予单位】：黑龙江八一农垦大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：F426.72;F406.72

【参考文献】